This message contains images. If you don't see images, click here to view.
Advertise in this news brief.

Text Version    RSS    Subscribe    Unsubscribe    Archive    Media Kit           April 01, 2015

Home     About SGO    Education    Membership    Clinical Practice    Public Policy    Blog    Partnerships    Store


Mixed results for bevacizumab plus chemo in ovarian cancer
MedPage Today
Women with recurrent, platinum-sensitive ovarian cancer obtained an unprecedented survival benefit with a chemotherapy-bevacizumab (Avastin) combination, but the improvement still failed to achieve statistical significance. Patients who received carboplatin, paclitaxel, and bevacizumab had a median overall survival (OS) of 42.2 months compared with 37.3 months for platinum-taxane doublet. Nonetheless, the 5-month difference just missed the trial's cutoff for statistical significance. Bevacizumab-treated patients did have a statistically significant improvement in progression-free survival (PFS), a secondary endpoint, as reported at the Society of Gynecologic Oncology meeting.
   Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Record-breaking numbers for 2015 SGO Annual Meeting
SGO reached the 2,000-member milestone during this week’s Annual Meeting on Women’s Cancer in Chicago, and broke a meeting registration record with 2,064 attendees. Enjoy conference photos and mark your calendar for the 47th Annual Meeting from March 19 through 22, 2016, in San Diego, CA.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Ovarian cancer treatment set to improve following biomarker discovery
Medical News Today
Resistance to chemotherapy is a major reason that patients with the most malignant form of ovarian cancer do not have a good chance of survival. Now researchers have discovered a biomarker that should improve prospects for patients by indicating how their bodies are likely to react to chemotherapy. The researchers, who report their findings in the British Journal of Cancer, suggest the discovery of the biomarker could lead to better treatment options for patients with high-grade serous ovarian cancer (HGSC).
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

  ChemoFx Improves Ovarian Cancer Outcomes
ChemoFx® provides invaluable information to physicians choosing from 20+ equivalent treatment recommendations without prior knowledge of how individual patients may respond. ChemoFx determines platinum resistance in primary ovarian cancer and demonstrates longer overall survival by 14 months in recurrent ovarian cancer, making it instrumental in improving patient outcomes.


Guidance issued for endometrial cancer, hints for diagnosis
Medscape (Free login required)
The American College of Obstetricians and Gynecologists and the Society of Gynecologic Oncology have issued new guidance for endometrial cancer. The practice bulletin was published in the April issue of Obstetrics & Gynecology. "A thorough understanding of the epidemiology, pathophysiology, and diagnostic and management strategies for this type of cancer allows the obstetrician–gynecologist to identify women at increased risk, contribute toward risk reduction, and facilitate early diagnosis," the bulletin states.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Carboplatin noninferior to cisplatin for metastatic, recurrent cervical cancer
Carboplatin-based chemotherapy should be a standard treatment option for metastatic or recurrent cervical cancer, according to findings from a randomized phase 3 trial. Palliative chemotherapy is an option for women with metastatic or recurrent cervical cancer. Cisplatin has been the active agent most often used in that setting. Combining cisplatin with paclitaxel has vastly improved response rate and PFS while maintaining a tolerable level of toxicity, according to study background published in the Journal of Clinical Oncology.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Female IBD patients should monitor cervical cancer screenings
Women afflicted with inflammatory bowel disease (IBD) are at higher risk for cervical dysplasia and cancer. A new study published in Clinical Gastroenterology and Hepatology, underscored the significance for female IBD patients and their physicians to cautiously follow the recommended cervical cancer screening guidelines. The research team conducted a population-based, case-controlled study enrolling a total of 27,408 women with IBD in Denmark, during 35-year period.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Uncover Hereditary Cancer Risk for Your Patients
The average OB/GYN has 400 patients who meet criteria for further evaluation of hereditary cancer syndrome. Learn how to identify high-risk patients.
Advertise here!

To find out how to feature your company in the SGO News Brief and other advertising opportunities, Contact Geoffrey Forneret at 469-420-2629.


Fibroid morcellation gets boost from new study but procedure was linked to more leiomyosarcoma deaths
MedPage Today
A decision-tree analysis predicted fewer overall deaths, fewer surgical complications, and increased quality of life for women who underwent laparoscopic hysterectomy with morcellation compared with abdominal hysterectomy for presumed fibroid uterus, reported researchers. But there were more deaths from leiomyosarcoma after laparoscopic hysterectomy, wrote Matthew Siedhoff, MD, an ob/gyn physician at the University of North Carolina School of Medicine in Chapel Hill, and colleagues, in the American Journal of Obstetrics & Gynecology.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Visit the SGO Women's Cancer News archive page.


The birth and increasingly troubled life of Medicare
MedPage Today
On July 30, 1965, an 81-year-old Missourian proudly accepted the nation's first Medicare card. Former President Harry S. Truman was awarded this honor by his greatest admirer, President Lyndon B. Johnson. Johnson had been a young Texas congressman when Truman first proposed a national health insurance plan in 1945. Faced by implacable congressional opposition led by most Republicans and several conservative Democrats, national health insurance never had a chance and had disappeared ignominiously from national consideration even before Truman left office in 1952.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article


Cancer whole-genome sequencing: Present and future
Recent explosive advances in next-generation sequencing technology and computational approaches to massive data enable us to analyze a number of cancer genome profiles by whole-genome sequencing (WGS). To explore cancer genomic alterations and their diversity comprehensively, global and local cancer genome-sequencing projects, including ICGC and TCGA, have been analyzing many types of cancer genomes mainly by exome sequencing.
Share this article:   Share on FacebookTwitterShare on LinkedinE-mail article

Women's Cancer News
Colby Horton, Vice President of Publishing, 469.420.2601
Download media kit

Jessica Taylor, Senior Medical Editor, 202-684-7169  
Contribute news

Inclusion of advertisements does not constitute SGO endorsement of company products or services.

Be sure to add us to your address book or safe sender list so our emails get to your inbox. Learn how.

This edition of the Women's Cancer News was sent to ##Email##. To unsubscribe, click here. Did someone forward this edition to you? Subscribe here — it's free!

Recent issues

March 25, 2015
March 18, 2015
March 11, 2015
March 4, 2015

7701 Las Colinas Ridge, Ste. 800, Irving, TX 75063